Expectations of a post-pandemic recovery in surgical interventions such as orthopaedic implants did not play out - Cavan Images / Raffi Maghdessian As stock ideas go, Smith & Nephew has been a shocker. The thesis that a recovery in surgical interventions in a post-pandemic world would benefit the specialist provider of orthopaedic implants, sports medicine and advanced wound management products has not played out. Nor have profit margins and return on capital improved, despite efficiency programmes and an easing of the supply chain pressures that resulted from lockdowns. As result, we are sat on a 25pc book loss, only partly mitigated by just over 100p a share in dividends but if there is any good news here it is: we are not the only ones whose patience is wearing thin. The Swedish activist investor Cevian is now on the shareholder register and the share price is responding, in anticipation of some form of action or other, so this may be the final roll of the dice so far as the FTSE 100 member and the Questor portfolio are concerned. ADVERTISEMENT Chief executive officer Deepak Nath outlined a 12-point plan in autumn 2022, with the ultimate goal that the cost and efficiency benefits would drive the underlying profit margin to 20pc by 2025. This year’s first-quarter results (1 May) at least featured no nasty surprises as Mr Nath reasserted guidance for 2024 of underlying sales growth of between 5pc and 6pc and an underlying margin of 18pc, an improvement on 2023’s 17.5pc (which itself represented a modest advance from 2022’s 17.3pc). However, even that 18pc figure means there is still work to be done. Ongoing weakness in the US hip and knee implant business, plus a year-on-year drop in sales at the advanced wound management business, meant the update did not inspire much market confidence, judging by how the share price continued to ebb to a mark nearly 40pc below that of five years ago. Enter Cevian. Activists have a fairly classic – indeed even predictable – playbook, and any chief executive who has not sat and thought about how their business looks relative to a typical activist approach really needs to do so. In sum, the activist investor tends to come with one (or more) of four possible thrusts: strategic change, including asset sales, a break up for preparing a firm for a bid; a change in capital allocation policy, designed to boost cash returns to investors via enhanced dividend or share buybacks; or operational improvements, through the closure or restructuring or underperforming divisions. The activist investor may also try boardroom change such as improvements in governance, whereby the activist looks to improve the skillset of the board relative to the company’s target industry, or reining in executive pay (if it is seen to be excessive) or even appoint its own people to the management team. In this case, it would be logical to assume that Cevian is looking for faster improvement in operational and financial performance, and perhaps more ambitious margin targets, whether this is achieved through a wider ranging cost-cutting plan or even changes to Smith & Nephew’s three-division structure, so that resources can be allocated to the best effect. One option that does not seem likely, for the moment at least, is hectoring the FTSE 100 index constituent to shift its listing to New York from London. Granted, Smith & Nephew trades at a big valuation discount to American rival Stryker, at 20 times forward earnings compared to more than 30 times, and at a discount to another transatlantic peer, Zimmer Biomet, which trades on a multiple in the low 20s. But Smith & Nephew’s margins lag those of the comparable American firms and thus is it quite legitimate to argue the discount is merited. If the margin gap closes, so could the valuation gap and that is still the job at hand for Mr Nath and management, albeit perhaps now in the face of greater scrutiny now that Cevian is a shareholder. Shifting the listing to a different stock exchange would not make Smith & Nephew a better company and to think otherwise would be a mistake. As fund management legend John Bogle, the founder of Vanguard, once noted: “The stock market is a giant distraction from the business of investing. In the long run investing is about returns earned by businesses – not the stock market.” If Smith & Nephew can improve its margins, cash flow and returns on capital, then shareholders are in business. If not, the stock is dead money at best, but the prospect of a Cevian-inspired shake-up at least improves our chances or erasing the paper loss we currently hold on the stock. Questor says: hold Ticker: SN Share price at close: £10.62 Read the latest Questor column on telegraph.co.uk every Sunday, Monday, Tuesday, Wednesday and Thursday from 8pm Read Questor’s rules of investment before you follow our tips
Questor: This stock tip has been a shocker – but there’s hope yet
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...